503A vs 503B Compounding Pharmacies: Regulatory Differences Explained
State-regulated compounding pharmacy or FDA-regulated outsourcing facility? The structural difference shaped the entire compounded GLP-1 market — and now shapes what's legal post-shortage. Here's what each designation actually means.
The bottom line
A 503A pharmacy compounds patient-specific prescriptions one at a time, regulated primarily by state boards of pharmacy. A 503B outsourcing facility manufactures sterile drugs in bulk for office use, regulated directly by FDA under current Good Manufacturing Practices (cGMP). Both became central to the GLP-1 conversation when the FDA shortage list permitted compounded semaglutide and tirzepatide. Both lost that pathway when the FDA declared the shortages resolved in 2024–2025.
For patients today, the practical question is no longer "503A or 503B" — it is whether any compounded version remains available legally and what FDA-approved alternatives exist.
The legal foundation
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act were both established by the Drug Quality and Security Act (DQSA) of 2013 — passed in direct response to the New England Compounding Center (NECC) meningitis outbreak that killed more than 100 patients from contaminated steroid injections. The DQSA created two distinct regulatory tracks for pharmacy compounding.
Side-by-side: how they actually differ
| Attribute | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Primary regulator | State board of pharmacy | FDA, directly |
| Prescription requirement | Patient-specific Rx required for each preparation | Can compound without patient-specific Rx (office use) |
| Quality standard | USP <795>, <797>, <800> | cGMP (21 CFR 210/211) — same as drug manufacturers |
| Batch size | Limited; effectively per-patient | Bulk batches permitted |
| FDA registration | Not required | Required |
| FDA inspection | For-cause only (rare) | Routine FDA inspection schedule |
| Environmental monitoring | Every 6 months | Every production shift in primary compounding areas |
| End user | Individual patients (home use) | Healthcare facilities (office/clinic use) |
| Annual fee to FDA | None | Required |
What 503A pharmacies actually do
A 503A pharmacy is what most people think of as a "traditional compounding pharmacy." When a clinician prescribes a custom dose, an alternate dosage form (oral suspension instead of tablet for a child who can't swallow pills, dye-free formulation for a patient with an excipient allergy), or an unusual combination, the 503A pharmacy compounds it under a patient-specific prescription. The pharmacy must be DEA-registered if it handles controlled substances and licensed by the state board where it operates and any state it ships into.
Quality is governed by United States Pharmacopoeia (USP) chapters: USP <795> for non-sterile compounding, <797> for sterile, and <800> for hazardous drug handling. These are real standards — but they are not cGMP. There is no requirement for a separate quality department, no mandatory potency testing on every batch, no pre-market FDA review of the formulation, and no requirement for full process validation.
What 503B outsourcing facilities do
A 503B is essentially a hybrid: it compounds (it can produce drugs that are not FDA-approved formulations), but it does so under cGMP — the same manufacturing-quality framework as branded and generic drug makers. 503B facilities can produce sterile medications in bulk for hospitals, clinics, ambulatory surgery centers, and physician offices for office use, without a patient-specific prescription.
Despite "outsourcing facility" implying scale, a 503B facility is technically not a manufacturer. Products made by 503Bs are not subject to the same product liability framework as FDA-approved cGMP-manufactured drugs. Hospital pharmacies that purchase from 503Bs typically structure contracts to address adverse event reporting, recall responsibility, and quality-failure cost allocation.
Where the GLP-1 story fits
Neither 503A nor 503B facilities are normally permitted to compound a drug that is "essentially a copy" of an FDA-approved product. The exception: if the FDA-approved drug is on FDA's drug shortage list at the time of compounding, the prohibition is lifted.
Wegovy (semaglutide) was added to the FDA shortage list in March 2022. Ozempic followed in August 2022. Tirzepatide (Mounjaro/Zepbound) was added in December 2022. For more than two years, the shortage status created a legal pathway for both 503A pharmacies and 503B facilities to compound essentially-copy versions of these GLP-1 drugs — and a multi-billion-dollar telehealth industry built around exactly that pathway.
The shortage is over — what changed
FDA resolved the tirzepatide shortage on December 19, 2024, and the semaglutide shortage on February 21, 2025. With the shortage status lifted, the legal pathway for compounded essentially-copies closed.
| Drug | Shortage resolved | 503A enforcement deadline | 503B enforcement deadline |
|---|---|---|---|
| Tirzepatide | Dec 19, 2024 | Feb 18, 2025 | Mar 19, 2025 |
| Semaglutide | Feb 21, 2025 | Apr 22, 2025 | May 22, 2025 |
After these dates, FDA stated it does not intend to refrain from enforcement action against compounders producing essentially-copy versions of these drugs. The Outsourcing Facilities Association filed lawsuits challenging both shortage-resolution determinations; FDA's enforcement discretion was maintained until district court rulings on preliminary injunction motions.
What's still legal — and what isn't
The "essentially a copy" prohibition has limited exceptions. Per FDA guidance, a compounded preparation may not be considered "essentially a copy" if there is a documented clinical difference for an individual patient — for example:
- Removal of an inactive ingredient due to documented patient allergy
- Change in dosage form (e.g., tablet to liquid for a patient unable to swallow)
- Combination with another active ingredient creating a meaningfully different product
- Different dosage strength not commercially available — but only when clinically justified per-patient
What does not qualify: the same drug, same route, same dosage strength, dispensed at a lower price than the FDA-approved version. That is precisely the use case that drove 2022–2024 compounded GLP-1 telehealth — and it is no longer on the table for either 503A or 503B compounders.
Related coverage Trial tracker including SURMOUNT-5 and other ongoing GLP-1 studies →Why the distinction still matters for patients
Even with the essentially-copy pathway closed, the regulatory difference between 503A and 503B has practical implications. Some compounders are still producing semaglutide and tirzepatide products under "individual patient need" justifications — different concentrations, oral or sublingual formulations, or combinations with vitamins (B12, NAD+ derivatives). Whether these products are legitimately differentiated or are workarounds of the essentially-copy rule is the open enforcement question.
FDA explicitly warned the public about non-sterile compounded semaglutide and tirzepatide injections, stating that administration of a non-sterile drug intended to be sterile may result in serious and potentially life-threatening adverse health consequences including infections and sepsis. This warning is independent of the shortage-resolution issue — it concerns underlying compounding quality.
The broader oversight gap
503B facilities are required to undergo routine FDA inspection — but the agency has acknowledged that some 503B-registered facilities have never been inspected. As of late 2024, multiple registered 503B facilities had filed required biannual product reports without ever receiving an FDA inspection. The Partnership for Safe Medicines documented that of 39 such uninspected facilities, 24 were operating only under 503A licensure (state-licensed), and 15 held state manufacturer or distributor licenses with varying state requirements. This is the regulatory landscape consumers are navigating when they encounter "FDA-registered 503B" branding.
For patients who want to stay within the FDA-approved framework
For patients exploring compounded options that meet differentiation criteria
The takeaway
The 503A versus 503B distinction is structural — different regulators, different quality standards, different end users. For most of 2022–2024, the distinction mattered less to patients than the simple fact that both could legally produce inexpensive semaglutide and tirzepatide. With the shortage resolved, the distinction matters more again: 503B facilities operating under cGMP retain the higher quality framework even as the essentially-copy pathway closes; 503A pharmacies retain patient-specific compounding flexibility for genuinely differentiated products.
The cleanest path for patients today, regulatory-wise, is the FDA-approved product through a licensed pharmacy — which is what brand-name semaglutide and tirzepatide programs offer. The compounded path remains available where genuine clinical differentiation exists, but the legal and quality terrain is now meaningfully more complicated than it was a year ago.
Primary Sources
- U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Drug Quality and Security Act (DQSA), Pub. L. No. 113-54, 127 Stat. 587 (2013). Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
- United States Pharmacopeia. USP General Chapters <795>, <797>, <800>. usp.org/compounding
- FDA. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A. Guidance for Industry.
- Partnership for Safe Medicines. What is a 503B outsourcing facility, and why are so many of them uninspected by FDA? safemedicines.org/2025/07/503b-fda-inspections.html
- Pharmacy Times. Regulatory Considerations Regarding the 503B to 503A Compounding Model For Community Pharmacies. pharmacytimes.com
- FDA. Compounded Versions of GLP-1 Drugs (Safety Communication, November 2024).